These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 28423656)
1. Effect of Y6, an epigallocatechin gallate derivative, on reversing doxorubicin drug resistance in human hepatocellular carcinoma cells. Wen Y; Zhao RQ; Zhang YK; Gupta P; Fu LX; Tang AZ; Liu BM; Chen ZS; Yang DH; Liang G Oncotarget; 2017 May; 8(18):29760-29770. PubMed ID: 28423656 [TBL] [Abstract][Full Text] [Related]
2. The epigallocatechin gallate derivative Y6 reduces the cardiotoxicity and enhances the efficacy of daunorubicin against human hepatocellular carcinoma by inhibiting carbonyl reductase 1 expression. Zhou H; Fu LX; Li L; Chen YY; Zhu HQ; Zhou JL; Lv MX; Gan RZ; Zhang XX; Liang G J Ethnopharmacol; 2020 Oct; 261():113118. PubMed ID: 32621953 [TBL] [Abstract][Full Text] [Related]
3. The epigallocatechin gallate derivative Y Liao ZH; Zhu HQ; Chen YY; Chen RL; Fu LX; Li L; Zhou H; Zhou JL; Liang G J Ethnopharmacol; 2020 Sep; 259():112852. PubMed ID: 32278759 [TBL] [Abstract][Full Text] [Related]
4. Epigallocatechin-3-gallate promotes apoptosis and reversal of multidrug resistance in esophageal cancer cells. Liu L; Ju Y; Wang J; Zhou R Pathol Res Pract; 2017 Oct; 213(10):1242-1250. PubMed ID: 28964574 [TBL] [Abstract][Full Text] [Related]
5. Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer. Liang G; Tang A; Lin X; Li L; Zhang S; Huang Z; Tang H; Li QQ Int J Oncol; 2010 Jul; 37(1):111-23. PubMed ID: 20514403 [TBL] [Abstract][Full Text] [Related]
6. Reversal of cancer multidrug resistance by green tea polyphenols. Mei Y; Qian F; Wei D; Liu J J Pharm Pharmacol; 2004 Oct; 56(10):1307-14. PubMed ID: 15482646 [TBL] [Abstract][Full Text] [Related]
7. Reversal effect of quercetin on multidrug resistance via FZD7/β-catenin pathway in hepatocellular carcinoma cells. Chen Z; Huang C; Ma T; Jiang L; Tang L; Shi T; Zhang S; Zhang L; Zhu P; Li J; Shen A Phytomedicine; 2018 Apr; 43():37-45. PubMed ID: 29747752 [TBL] [Abstract][Full Text] [Related]
8. (-)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line. Farabegoli F; Papi A; Bartolini G; Ostan R; Orlandi M Phytomedicine; 2010 Apr; 17(5):356-62. PubMed ID: 20149610 [TBL] [Abstract][Full Text] [Related]
9. The epigallocatechin gallate derivative Y Wen Y; Zhao R; Gupta P; Fan Y; Zhang Y; Huang Z; Li X; Su Y; Liao L; Xie YA; Yang D; Chen ZS; Liang G Acta Pharm Sin B; 2019 Mar; 9(2):316-323. PubMed ID: 30972279 [TBL] [Abstract][Full Text] [Related]
10. [MDR-reversing effect of two components of catechin on human hepatocellular carcinoma BEL-7404/Adr in vitro]. Liang G; Zhang S; Huang ZM; Tang AZ Ai Zheng; 2004 Apr; 23(4):401-5. PubMed ID: 15087027 [TBL] [Abstract][Full Text] [Related]
11. [Impact of epigallocatechin gallate on gene expression profiles of human hepatocellular carcinoma cell lines BEL7404/ADM and BEL7402/5-FU]. Tang HH; Zhou M; Liang G Ai Zheng; 2008 Oct; 27(10):1056-64. PubMed ID: 18851785 [TBL] [Abstract][Full Text] [Related]
12. In vivo reversal of doxorubicin resistance by (-)-epigallocatechin gallate in a solid human carcinoma xenograft. Zhang Q; Wei D; Liu J Cancer Lett; 2004 May; 208(2):179-86. PubMed ID: 15142676 [TBL] [Abstract][Full Text] [Related]
13. Downregulation of NPM reverses multidrug resistance in human hepatoma cells via inhibition of P-glycoprotein expression. Luo F; Li H; Liang J; Jia H; Li X; Xiao H; He X; He J; Tian Y; Zhao H Mol Med Rep; 2017 Apr; 15(4):2360-2368. PubMed ID: 28259962 [TBL] [Abstract][Full Text] [Related]
14. siRNA Targeting of MDR1 Reverses Multidrug Resistance in a Nude Mouse Model of Doxorubicin-resistant Human Hepatocellular Carcinoma. Yang H; Ding R; Tong Z; Huang J; Shen L; Sun YU; Liao J; Yang Z; Hoffman RM; Wang C; Meng X Anticancer Res; 2016 Jun; 36(6):2675-82. PubMed ID: 27272776 [TBL] [Abstract][Full Text] [Related]
15. Inhibitory effects of epigallocatechin-3-gallate on cell proliferation and the expression of HIF-1α and P-gp in the human pancreatic carcinoma cell line PANC-1. Zhu Z; Wang Y; Liu Z; Wang F; Zhao Q Oncol Rep; 2012 May; 27(5):1567-72. PubMed ID: 22367292 [TBL] [Abstract][Full Text] [Related]
16. Modulation of P-glycoprotein function and reversal of multidrug resistance by (-)-epigallocatechin gallate in human cancer cells. Qian F; Wei D; Zhang Q; Yang S Biomed Pharmacother; 2005 Apr; 59(3):64-9. PubMed ID: 15795098 [TBL] [Abstract][Full Text] [Related]
17. Reversal effect of bufalin on multidrug resistance in human hepatocellular carcinoma BEL-7402/5-FU cells. Gu W; Liu L; Fang FF; Huang F; Cheng BB; Li B Oncol Rep; 2014 Jan; 31(1):216-22. PubMed ID: 24173654 [TBL] [Abstract][Full Text] [Related]
18. Epigallocatechin Gallate Derivative Y6 Reverses Oxaliplatin Resistance in Hepatocellular Carcinoma via Targeting the MiR-338-3p/HIF-1α/TWIST Axis to Inhibit EMT. Huang C; Wang SH; Liu TT; Wu MY; Cai KN; Xie ZH; Zhao RQ; Wen Y Recent Pat Anticancer Drug Discov; 2024 Jul; ():. PubMed ID: 38994622 [TBL] [Abstract][Full Text] [Related]
19. Modulation of multidrug resistant in cancer cells by EGCG, tannic acid and curcumin. Li H; Krstin S; Wink M Phytomedicine; 2018 Nov; 50():213-222. PubMed ID: 30466981 [TBL] [Abstract][Full Text] [Related]
20. Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition. Gao M; Xu Y; Qiu L J Liposome Res; 2017 Jun; 27(2):151-160. PubMed ID: 27250110 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]